JP2002522039A5 - - Google Patents

Download PDF

Info

Publication number
JP2002522039A5
JP2002522039A5 JP2000563313A JP2000563313A JP2002522039A5 JP 2002522039 A5 JP2002522039 A5 JP 2002522039A5 JP 2000563313 A JP2000563313 A JP 2000563313A JP 2000563313 A JP2000563313 A JP 2000563313A JP 2002522039 A5 JP2002522039 A5 JP 2002522039A5
Authority
JP
Japan
Prior art keywords
envelope protein
hiv envelope
antibody
hiv
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000563313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522039A (ja
JP4637356B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/017596 external-priority patent/WO2000007631A1/en
Publication of JP2002522039A publication Critical patent/JP2002522039A/ja
Publication of JP2002522039A5 publication Critical patent/JP2002522039A5/ja
Application granted granted Critical
Publication of JP4637356B2 publication Critical patent/JP4637356B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000563313A 1998-08-04 1999-08-04 広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション Expired - Fee Related JP4637356B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9526798P 1998-08-04 1998-08-04
US60/095,267 1998-08-04
PCT/US1999/017596 WO2000007631A1 (en) 1998-08-04 1999-08-04 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response

Publications (3)

Publication Number Publication Date
JP2002522039A JP2002522039A (ja) 2002-07-23
JP2002522039A5 true JP2002522039A5 (https=) 2010-01-28
JP4637356B2 JP4637356B2 (ja) 2011-02-23

Family

ID=22251048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000563313A Expired - Fee Related JP4637356B2 (ja) 1998-08-04 1999-08-04 広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション

Country Status (7)

Country Link
EP (1) EP1104310B1 (https=)
JP (1) JP4637356B2 (https=)
AT (1) ATE435034T1 (https=)
AU (1) AU762376C (https=)
CA (1) CA2338886C (https=)
DE (1) DE69941051D1 (https=)
WO (1) WO2000007631A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW511388B (en) 2000-03-28 2002-11-21 Koninkl Philips Electronics Nv Passive radiator having mass elements
JP2006504435A (ja) * 2002-05-10 2006-02-09 ザ ヘンリー エム. ジャクソン ファウンデイション HIV−1のgp120のgp41への相互作用部位
WO2004113369A1 (de) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh NEUE OBERFLÄCHENPROTEIN- (HbsAg-) VARIANTE DES HEPATITIS B VIRUS
EP1638995B1 (de) 2003-06-20 2015-08-26 Siemens Healthcare Diagnostics Products GmbH Neue oberflächenprotein-(hbsag-) variante des hepatitis b virus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Hiv−1免疫原性組成物
CA2705373A1 (en) * 2007-11-12 2009-08-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Hiv-1 envelope glycoprotein oligomer and methods of use
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
JP2014501225A (ja) 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP2892554B1 (en) 2012-09-07 2020-08-26 Emory University Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
WO1992020373A1 (en) * 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69311764T2 (de) * 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
GB9318901D0 (en) * 1993-09-13 1993-10-27 Centre Nat Rech Scient Multiple branch peptide construction

Similar Documents

Publication Publication Date Title
NZ333500A (en) Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV
EP2425848A3 (en) Influenza immunogen and vaccine
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
CA2413546A1 (en) Modification of hepatitis b core antigen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
WO2001096368A3 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
JP2002522039A5 (https=)
KR920703102A (ko) 인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines)
CN115850506B (zh) 一种cd4辅助性t细胞表位融合肽及其疫苗
JP2002533125A5 (https=)
JPH0327400A (ja) B型肝炎ウイルスコア抗原粒子
EP0693937A4 (en) HIV-1 VACCINES, CORRESPONDING ANTIBODY COMPOSITIONS AND THEIR THERAPEUTIC AND PROPHYLACTIC USE
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
JP2004537308A5 (https=)
WO1999017789A1 (en) Peptide compositions for the treatment and prevention of hiv infection
JP2002534481A5 (https=)
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
CN102000329B (zh) 一种改造的非致病细菌来源的鞭毛素粘膜佐剂及制备方法
WO2006050219A3 (en) Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2084386A1 (en) Hiv antigen
Li et al. A Divalent Chikungunya and Zika Nanovaccine with Thermostable Self‐Assembly Multivalent Scaffold LS‐SUMO
WO2003097673B1 (en) Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
CN120305395A (zh) mRNA-LNPs布鲁氏菌疫苗、表达载体及其制备方法
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden